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108,687 patients in 10 years: Changes in risks, valve types, and
outcomes in the Society of Thoracic Surgeons National Database
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Objective: More than 200,000 aortic valve replacements are performed annually worldwide. We describe
changes in the aortic valve replacement population during 10 years in a large registry and analyze outcomes.
Methods: The Society of Thoracic Surgeons National Database was queried for all isolated aortic valve replace-
ments between January 1, 1997, and December 31, 2006. After exclusion for endocarditis and missing age or sex
data, 108,687 isolated aortic valve replacements were analyzed. Time-related trends were assessed by comparing
distributions of risk factors, valve types, and outcomes in 1997 versus 2006. Differences in case mix were sum-
marized by comparing average predicted mortality risks with a logistic regression model. Differences across
subgroups and time were assessed.
Results: There was a dramatic shift toward use of bioprosthetic valves. Aortic valve replacement recipients in
2006 were older (mean age 65.9 vs 67.9 years, P< .001) with higher predicted operative mortality risk (2.75
vs 3.25, P<.001); however, observed mortality and permanent stroke rate fell (by 24% and 27%, respectively).
Female sex, age older than 70 years, and ejection fraction less than 30%were all related to higher mortality, higher
stroke rate and longer postoperative stay. There was a 39% reduction in mortality with preoperative renal failure.
Conclusions: Morbidity and mortality of isolated aortic valve replacement have fallen, despite gradual increases
in patient age and overall risk profile. There has been a shift toward bioprostheses. Women, patients older than 70
years, and patients with ejection fraction less than 30% have worse outcomes for mortality, stroke, and postop-
erative stay.The first aortic valve replacement (AVR) was performed by
Harken 48 years ago.1 In the setting of aortic valve disease,
patients are predominantly seen with aortic stenosis, which
necessitates valve replacement. Ferguson and colleagues2
reviewed the Society of Thoracic Surgeons (STS) database
with regard to coronary artery bypass grafting. They found
that the population undergoing this procedure had aged
and was at higher risk yet had a lower mortality. Edwards
and associates3 developed a model for risk prediction in
the setting of valve replacement surgery. This model was
validated and proved accurate in predicting outcomes.
Two percent of the population have bicuspid aortic valves,
which are at risk for stenosis.4,5 Four percent of the elderly
population have significant aortic stenosis.6,7 The size of
the population older than 65 years will grow 50% between
2000 and 2030.8,9 Devices for transcatheter AVR are in de-
velopment and clinical investigation. Early results suggest
the feasibility of transcatheter valve therapy10,11; however,
standard outcome measures must continue to drive clinical
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The study population consisted of patients 20 years old or older who un-
derwent isolated AVR at STS-participating hospitals between January 1,
1997, and December 31, 2006. From an initial population of 115,163 iso-
lated AVR cases, we identified a subset of 108,791 patients (94.5%) with-
out a history of endocarditis. From these, we excluded 104 patients (0.1%)
with missing data on two key study variables, age and sex. The final study
population consisted of 108,687 patients from 928 participating hospitals
and surgeon groups. Although 928 participants contributed data during
the study period, the number of participants in any single calendar year
ranged from 365 to 756.
End Points
Outcome measures consisted of in-hospital mortality, permanent stroke,
and postoperative stay. Postdischarge 30-day mortality was not analyzed,
because this end point was not captured consistently by many participants
during the study period.
Analysis
The distributions of patient characteristics and outcomes were summa-
rized with percentages for categorical variables and means and medians
for continuous variables. Differences in the prevalence of risk factors and
outcomes in 1997 versus 2006 were assessed with stratified Mantel–Haens-
zel c2 statistics, with STS participant identity serving as the stratification
variable. Confidence intervals for the relative change in risk factorery c January 2009




AVR ¼ aortic valve replacement
STS ¼ Society of Thoracic Surgeons
prevalence in 1997 versus 2006 were calculated by fitting generalized linear
models with a log link function. SEs were calculated with an empirical sand-
wich estimator to account for correlation of observations within the same
participant.
To create a patient-level summary measure of case severity, we used lo-
gistic regression to estimate the probability of mortality for each patient in
the study sample. Explanatory variables consisted of age, sex, ejection frac-
tion, congestive heart failure, diabetes, renal failure, cerebrovascular acci-
dent, peripheral vascular disease, myocardial infarction, and surgical
status. The patient’s estimated probability of death is a simple summary mea-
sure that combines several individual risk factors into a single number. The
observed to expected ratio statistic was then used to compare temporal trends
in actual mortality with the average predicted probability from the logistic
regression model. For each calendar year, the risk-adjusted mortality was
calculated by multiplying the observed to expected ratio times the overall
mortality during the study period. Finally, a test of trend was calculated
by adding surgery year to the logistic regression model described previously
and testing whether the coefficient was zero.
Missing Data
Patients with missing data were included in the denominator when report-
ing the prevalence of binary (yes/no) risk factors. We report the percentage
of patients for whom each risk factor was coded as present and the percent-
age of patients for whom the data were unavailable. We included missing
data in the denominator, because patient records frequently list risk factors
that are present without enumerating the risk factors that are absent. For
four variables (chronic obstructive pulmonary disease, New York Heart As-
sociation functional class, ejection fraction, and aortic insufficiency), there
were large differences in the frequencies of missing data in 1997 and
2006. For these variables, we repeated the analysis with the subset of partic-
ipants with at least 90% complete data for the variable. Records missing data
for outcomes (mortality and stroke) were imputed to the no category.
RESULTS
Both the number of AVRs and the number of participating
programs increased during the 10-year study period
(Table 1). Table 2 comprehensively outlines patient popula-
tion characteristics in the overall population, in 1997, and
in 2006. Selected patient characteristics are presented inThe Journal of Thoracic andTable 3. The incidences of age older than 70 years, obesity,
diabetes, hypertension, chronic obstructive pulmonary dis-
ease, cerebrovascular disease, previous stroke, and renal
failure all increased during the 10-year study period. The
use of bioprosthetic valves increased to 78.4% of total
valves used, whereas the mechanical valve use declined to
20.5% (P< .000001; Figure 1).
Despite increases in comorbidity and predicted risk of
death after AVR, the overall observed mortality and risk-
adjusted mortality decreased (P<.01; Table 4 and Figure 2).
Similarly, the incidence of stroke declined during the last 10
years (P< .05; Table 4 and Figure 3). Subgroup analysis
(Table 5) demonstrated that mortality was higher for women
than for men overall (not shown) and in the 1997 and 2006
populations (P < .01; Figure 4). Nonwhite patients had
a higher mortality from AVR, which was not improved dur-
ing the study period (Table 5). Age greater than 70 years,
diabetes, peripheral vascular disease, ejection fraction less
than 30%, and body mass index were all associated with
higher mortality (Table 5). Mortality decreased more than
30% between 1997 and 2006 in the presence of diabetes,
nonurgent cases, and renal failure and in the younger than
55 years, 55 to 60 years, 60 to 65 years, and older than 85
years age groups (Figure 5). In 2006 there were 2,431 pa-
tients who had undergone previous cardiac surgery and their
associated mortality was 6.17%. By comparison, there were
12,966 patients with no prior heart surgery and the mortality
was 2.35% (not shown). Stroke was reduced in the 55 to 60
years and the 65 to 70 years age groups (Figure 6). Overall
stay was unchanged during the study period (not shown).
Age older than 75 years, female sex, and ejection fraction
less than 30% were associated with longer median stay
(9.23 days vs 7.06 days, 7.80 days vs 7.40 days, and 9.53
days vs 7.67 days, respectively, P< .01 for all).
DISCUSSION
We defined a population of patients undergoing AVR in
STS-participating North American centers from 1997 to
2006. Methods used in this study allow for completeness
and accuracy of database information, as delineated inTABLE 1. Numbers of patients and participants by year of surgery
Isolated atrial valve replacement recipients Participants
Year Patients in database Total Excluding endocarditis Excluding missing age or sex Total In study population
1997 252,688 9,932 9,421 9,407 466 447
1998 240,590 10,108 9,570 9,551 460 431
1999 210,295 9,108 8,612 8,597 380 367
2000 200,804 9,039 8,584 8,562 365 359
2001 205,418 9,656 9,145 9,135 422 410
2002 227,783 11,342 10,719 10,705 499 485
2003 232,044 12,070 11,358 11,355 549 537
2004 235,335 12,671 11,948 11,947 616 594
2005 250,028 14,907 14,034 14,031 709 688
2006 258,417 16,330 15,400 15,397 756 742Cardiovascular Surgery c Volume 137, Number 1 83
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DTABLE 2. Distribution of patient characteristics in study population: Overall, in 1997, and in 2006
Overall (n ¼ 108,687) In 1997 (n ¼ 9407) In 2006 (n ¼ 15,397) P value
Demographic characteristics
Age* (y) <.0001
Median 69.00 69.00 70
25th 59.00 58.00 60
75th 77.00 76.00 78
Mean 66.90 65.91 67.91
Dichotomous age (No.)
<70 y 54,363 (50.02%) 4946 (52.58%) 7368 (47.85%) <.0001
70 y 54,324 (49.98%) 4461 (47.42%) 8029 (52.15%)
Age ranges (No.) <.0001
<55 y 19,659 (18.09%) 1857 (19.74%) 2470 (16.04%)
55 to<60 y 9371 (8.62%) 719 (7.64%) 1344 (8.73%)
60 to<65 y 11,120 (10.23%) 1000 (10.63%) 1595 (10.36%)
65 to<70 y 14,213 (13.08%) 1370 (14.56%) 1959 (12.72%)
70 to<75 y 17,349 (15.96%) 1654 (17.58%) 2283 (14.83%)
75 to<80 y 18,610 (17.12%) 1547 (16.45%) 2707 (17.58%)
80 to<85 y 13,127 (12.08%) 911 (9.68%) 2180 (14.16%)
85 to<90 y 4556 (4.19%) 294 (3.13%) 765 (4.97%)
90 y 682 (0.63%) 55 (0.58%) 94 (0.61%)
Sex (No.) .7097
Male 62,013 (57.06%) 5382 (57.21%) 8827 (57.33%)
Female 46,674 (42.94%) 4025 (42.79%) 6570 (42.67%)
Ethnicity (No.)
Missing 1951 (1.80%) 288 (3.06%) 99 (0.64%) .0010
White 95,140 (87.54%) 8164 (86.79%) 13453 (87.37%)
Nonwhite 11,596 (10.67%) 955 (10.15%) 1845 (11.98%)
Risk factors
Body mass index (No.) <.0001
Missing 1964 (1.81%) 445 (4.73%) 85 (0.55%)
<30 kg/m2 69,810 (64.23%) 6387 (67.90%) 9502 (61.71%)
30 kg/m2 36,913 (33.96%) 2575 (27.37%) 5810 (37.73%)
Diabetes (No.) <.0001
Missing 1314 (1.21%) 448 (4.76%) 21 (0.14%)
No 85405 (78.58%) 7505 (79.78%) 11460 (74.43%)
Yes 21968 (20.21%) 1454 (15.46%) 3916 (25.43%)
Type 1 diabetes (No.)
Missing 1703 (1.57%) 520 (5.53%) 32 (0.21%) .0008
No 101,280 (93.19%) 8451 (89.84%) 14,375 (93.36%)
Yes 5704 (5.25%) 436 (4.63%) 990 (6.43%)
Hypertension (No.) <.0001
Missing 900 (0.83%) 303 (3.22%) 18 (0.12%)
No 39713 (36.54%) 4241 (45.08%) 4292 (27.88%)
Yes 68074 (62.63%) 4863 (51.7%) 11087 (72.01%)
Surgical status (No.) <.0001
Missing 373 (0.34%) 63 (0.67%) 17 (0.11%)
Elective 88,016 (80.98%) 7896 (83.94%) 12,042 (78.21%)
Urgent 19,361 (17.81%) 1318 (14.01%) 3252 (21.12%)
Emergency 808 (0.74%) 101 (1.07%) 80 (0.52%)
Emergency salvage 129 (0.12%) 29 (0.31%) 6 (0.04%)
Nonelective status (No.) <.0001
Missing 373 (0.34%) 63 (0.67%) 17 (0.11%)
No 88,016 (80.98%) 7896 (83.94%) 12,042 (78.21%)
Yes 20,298 (18.68%) 1448 (15.39%) 3338 (21.68%)
Chronic obstructive pulmonary disease (No.) .0005
Missing 17,641 (16.23%) 5575 (59.26%) 70 (0.45%)
No 73,908 (68.00%) 3243 (34.47%) 12,262 (79.64%)
Yes 17,138 (15.77%) 589 (6.26%) 3065 (19.91%)
Chronic obstructive pulmonary disease in subset (No.) <.0001
Missing 257 (0.29%) 17 (0.48%) 15 (0.10%)
No 71,299 (80.89%) 2992 (85.12%) 12,130 (79.92%)
Yes 16,582 (18.81%) 506 (14.40%) 3033 (19.98%)84 The Journal of Thoracic and Cardiovascular Surgery c January 2009




Overall (n ¼ 108,687) In 1997 (n ¼ 9407) In 2006 (n ¼ 15,397) P value
Peripheral vascular disease (No.) .6522
Missing 1568 (1.44%) 562 (5.97%) 29 (0.19%)
No 97,874 (90.05%) 8074 (85.83%) 13,969 (90.73%)
Yes 9245 (8.51%) 771 (8.20%) 1399 (9.09%)
Cerebrovascular disease (No.) <.0001
Missing 1696 (1.56%) 636 (6.76%) 29 (0.19%
No 95,659 (88.01%) 8059 (85.67%) 13,459 (87.41%)
Yes 11332 (10.43%) 712 (7.57%) 1909 (12.40%)
Cerebrovascular accident (No.) .7272
Missing 1513 (1.39%) 536 (5.70%) 29 (0.19%)
No 100,661 (92.62%) 8357 (88.84%) 14,397 (93.51%)
Yes 6513 (5.99%) 514 (5.46%) 971 (6.31%)
Renal failure (No.) .0135
Missing 1576 (1.45%) 542 (5.76%) 27 (0.18%)
No 101,719 (93.59%) 8484 (90.19%) 14,521 (94.31%)
Yes 5392 (4.96%) 381 (4.05%) 849 (5.51%)
Preoperative dialysis (No.) .3389
Missing 1705 (1.57%) 578 (6.14%) 29 (0.19%)
No 105,344 (96.92%) 8701 (92.49%) 15,104 (98.10%)
Yes 1638 (1.51%) 128 (1.36%) 264 (1.71%)
Immunosuppressive treatment (No.) .0016
Missing 1785 (1.64%) 605 (6.43%) 64 (0.42%)
No 103,899 (95.59%) 8616 (91.59%) 14,885 (96.67%)
Yes 3003 (2.76%) 186 (1.98%) 448 (2.91%)
Previous cardiovascular interventions
Coronary artery bypass grafting (No.) <.0001
Missing 937 (0.86%) 203 (2.16%) 62 (0.40%)
No 97,956 (90.13%) 8582 (91.23%) 13,702 (88.99%)
Yes 9794 (9.01%) 622 (6.61%) 1633 (10.61%)
Valve surgery (No.) .0058
Missing 967 (0.89%) 257 (2.73%) 40 (0.26%)
No 101,518 (93.4%) 8490 (90.25%) 14,541 (94.44%)
Yes 6202 (5.71%) 660 (7.02%) 816 (5.3%)
Preoperative cardiac status
Myocardial infarction (No.) .0004
Missing 1594 (1.47%) 569 (6.05%) 30 (0.19%)
No 97,466 (89.68%) 8079 (85.88%) 13,809 (89.69%)
Yes 9627 (8.86%) 759 (8.07%) 1558 (10.12%)
Myocardial infarction within 21 d (No.) .0126
Missing 1917 (1.76%) 642 (6.82%) 36 (0.23%)
No 104,728 (96.36%) 8609 (91.52%) 15,057 (97.79%)
Yes 2042 (1.88%) 156 (1.66%) 304 (1.97%)
Congestive heart failure (No.) <.0001
Missing 1652 (1.52%) 510 (5.42%) 32 (0.21%)
No 65,837 (60.57%) 5016 (53.32%) 10,169 (66.05%)
Yes 41,198 (37.91%) 3881 (41.26%) 5196 (33.75%)
Angina (No.) .6543
Missing 1508 (1.39%) 503 (5.35%) 33 (0.21%)
No 77,586 (71.38%) 6302 (66.99%) 10,971 (71.25%)
Yes 29593 (27.23%) 2602 (27.66%) 4393 (28.53%)
Arrhythmia (No.) <.0001
Missing 1695 (1.56%) 592 (6.29%) 41 (0.27%)
No 89,475 (82.32%) 7047 (74.91%) 13,203 (85.75%)
Yes 17517 (16.12%) 1768 (18.79%) 2153 (13.98%)
New York Heart Association functional class (No.) <.0001
Missing 8877 (8.17%) 1819 (19.34%) 636 (4.13%)
I 14,690 (13.52%) 859 (9.13%) 2225 (14.45%)
II 28,866 (26.56%) 1613 (17.15%) 5348 (34.73%)
III 42,452 (39.06%) 3621 (38.49%) 5672 (36.84%)
IV 13,802 (12.70%) 1495 (15.89%) 1516 (9.85%)The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 1 85




Overall (n ¼ 108,687) In 1997 (n ¼ 9407) In 2006 (n ¼ 15,397) P value
New York Heart Association functional class in subset (No.) <.0001
Missing 416 (0.45%) 52 (0.86%) 25 (0.17%)
I 13,756 (14.97%) 777 (12.81%) 2177 (15.09%)
II 26,861 (29.23%) 1277 (21.05%) 5233 (36.26%)
III 38,539 (41.93%) 2797 (46.10%) 5532 (38.34%)
IV 12,339 (13.42%) 1164 (19.19%) 1463 (10.14%)
Ejection fraction (%) <.0001
N (% missing) 94,207 (13.32%) 7100 (24.52%) 14,169 (7.98%)
Median 55% 52% 56%
25th percentile 45% 41% 50%
75th percentile 61% 60% 62%
Mean 53.39% 51.86% 54.38%
Ejection fraction ranges (No.) .0003
Missing 14,480 (13.32%) 2307 (24.52%) 1228 (7.98%)
<30% 5488 (5.05%) 447 (4.75%) 715 (4.64%)
30% 88,719 (81.63%) 6653 (70.72%) 13,454 (87.38%)
Ejection fraction in subset (%) <.0001
N (% missing) 62,360 (2.52%) 2868 (3.01%) 10,925 (2.43%)
Median 55% 50% 56%
25th 45% 45% 50%
75th 60% 60% 62%
Mean 53.36% 51.34% 54.43%
Ejection fraction ranges in subset (No.) .0183
Missing 1614 (2.52%) 89 (3.01%) 272 (2.43%)
<30% 3460 (5.41%) 157 (5.31%) 539 (4.81%)
30% 58,900 (92.07%) 2711 (91.68%) 10,386 (92.76%)
Aortic stenosis (No.) <.0001
Missing 2273 (2.09%) 712 (7.57%) 61 (0.40%)
No 18,467 (16.99%) 1550 (16.48%) 2327 (15.11%)
Yes 87,947 (80.92%) 7145 (75.95%) 13,009 (84.49%)
Aortic insufficiency (No.) <.0001
Missing 10,916 (10.04%) 3233 (34.37%) 277 (1.80%)
No 46,062 (42.38%) 2472 (26.28%) 7831 (50.86%)
Yes 51,709 (47.58%) 3702 (39.35%) 7289 (47.34%)
Aortic insufficiency in subset (No.) .1996
Missing 442 (0.52%) 41 (1.52%) 31 (0.21%)
No 41,736 (49.15%) 1319 (48.76%) 7615 (52.38%)
Yes 42,744 (50.33%) 1345 (49.72%) 6891 (47.40%)
Operative data
Valve type (No.) <.0001
Missing 1947 (1.79%) 335 (3.56%) 72 (0.47%)
None 280 (0.26%) 24 (0.26%) 16 (0.10%)
M 35,284 (32.46%) 4695 (49.91%) 3164 (20.55%)
B 69,448 (63.90%) 4104 (43.63%) 12,069 (78.39%)
H 1192 (1.10%) 169 (1.80%) 20 (0.13%)
A 324 (0.30%) 72 (0.77%) 10 (0.06%)
R 147 (0.14%) 8 (0.09%) 12 (0.08%)
BA 65 (0.06%) 0 (0%) 34 (0.22%)
*There were no missing data regarding age.Tables 1 through 5. Despite increases in morbidity and pre-
dicted mortality, this study demonstrated improved mortal-
ity and stroke rates during the 10-year study period. For
patients younger than 60 years, mortality from AVR in
2006 was less than 1.0%; for those younger than 70 years,
1.3%; for those younger than 80 years, below 3.5%; and
for those under 85 years, below 5% (Table 5). Overall mor-
tality fell 24%, and risk-adjusted mortality fell 33%. As-
suming that the risk models that have been developed and86 The Journal of Thoracic and Cardiovascular Surgvalidated12-16 for heart valve surgery and the model devel-
oped by the STS and Duke Clinical Research Institute3 are
accurate, we conclude that surgical teams participating in
the STS database have dramatically improved performance
for isolated AVR.
With regard to specific subgroups, the population of
AVR recipients became older and more obese and had in-
creased incidences of diabetes, hypertension, pulmonary
disease, cerebrovascular disease, and renal failure duringery c January 2009
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DTABLE 3. Relative changes in frequency of selected patient characteristics between 1997 and 2006
Relative change 95% Confidence interval c2 P value
Age 70 y 10.0% 6.4% to 13.6% 31.997 <.0001
Female 0.3% 3.6% to 3.2% 0.025 .87513
Nonwhite 18.0% 2.8% to 35.6% 5.491 .01911
Body mass index 30 kg/m2 37.9% 31.7% to 44.3% 191.399 <.0001
Diabetes 64.6% 55.5% to 74.1% 299.396 <.0001
Type 1 diabetes 38.7% 22.7% to 56.8% 27.376 <.0001
Hypertension 39.3% 35.7% to 43.0% 603.955 <.0001
Nonelective operation 40.8% 20.9% to 64.1% 19.274 .00001
Emergency operation 51.6% 67.6% to27.8% 12.648 .00038
Chronic obstructive pulmonary disease 217.9% 165.0% to 281.5% 154.655 <.0001
Chronic obstructive pulmonary disease in subset 38.8% 23.9% to 55.5% 32.11 <.0001
Peripheral vascular disease 10.9% 3.9% to 27.9% 1.994 .15796
Cerebrovascular disease 63.8% 44.9% to 85.2% 62.422 <.0001
Cerebrovascular accident 15.4% 3.6% to 28.6% 6.729 .00949
Renal failure 36.1% 19.5% to 55.1% 21.581 <.0001
Dialysis 26.0% 0.9% to 57.3% 4.168 .04121
Immunosuppressant medication 47.2% 19.2% to 81.7% 12.913 .00033
Previous coronary artery bypass grafting 60.4% 45.0% to 77.5% 83.535 <.0001
Previous valve surgery 24.5% 32.6% to15.3% 23.248 <.0001
Previous myocardial infarction 25.4% 10.0% to 43.0% 11.433 .00072
Myocardial infarction within 21 d 19.1% 18.8% to 74.6% 0.799 .37146
Congestive heart failure 18.2% 23.9% to12.1% 29.7 <.0001
Angina 3.2% 5.6% to 12.7% 0.476 .49024
Arrhythmia 25.6% 31.3% to19.5% 53.366 <.0001
New York Heart Association functional class IV 38.1% 47.1% to27.4% 35.059 <.0001
New York Heart Association functional class IV in subset 47.2% 55.5% to37.2% 52.569 <.0001
Ejection fraction<30% 2.3% 15.9% to 13.6% 0.09 .76396
Ejection fraction<30% in subset 9.3% 24.1% to 8.2% 1.176 .27826
Aortic stenosis 11.2% 8.2% to 14.4% 55.839 <.0001
Aortic insufficiency 20.3% 11.9% to 29.3% 25.148 <.0001
Aortic insufficiency in subset 4.7% 14.6% to 6.4% 0.723 .39503
Mechanical valve 58.8% 61.8% to55.7% 549.909 <.0001
Bioprosthetic valve 79.7% 67.6% to 92.6% 273.527 <.0001the 10 years. Despite these changes, overall mortality fell
for each subgroup. It also fell for most patient subsets out-
lined in Table 5. Subgroup stroke rate also decreased dur-
ing the 10-year period despite increasing age and risk in
this AVR population (Table 5 and Figure 6). To a degree,
stroke and mortality are dependent, because stroke leads to
higher mortality. Nonetheless, for patients younger than 70
years, risk of stroke after AVR was 0.7% in 2006. Be-
tween the ages of 70 and 80 years, stroke rate in 2006
was less than 2.0%, and even for octogenarians, stroke
was less than 2.5% (Table 5 and Figure 6). Stroke rate
in this study was time dependent as well as age dependent.
Female patients had higher mortality, higher stroke rate,
and longer postoperative stay relative to male patients.
This was true for the overall population, the 1997 group,
and the 2006 group. Bridges and coworkers17 previously
demonstrated a relationship between size and outcome in
the STS database in the setting of AVR. Because female
patients have a smaller body size on average than doThe Journal of Thoracic andmale patients, the increased mortality among female pa-
tients is consistent with reports linking body size to out-
come. Factors that cause this effect of higher female
FIGURE 1. Percentage use of bioprosthetic valves relative to mechanical
valves from 1997 through 2006. Bioprosthetic valve use increased progres-
sively during 10 years. Asterisk indicates P< .000001.Cardiovascular Surgery c Volume 137, Number 1 87
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DTABLE 4. Patient characteristics and outcomes by year
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Expected mortality (%) 2.8% 2.9% 2.9% 2.9% 3.0% 3.1% 3.1% 3.1% 3.2% 3.2%
Observed mortality (%) 3.4% 3.3% 3.5% 3.3% 3.2% 2.9% 2.8% 2.8% 2.3% 2.6%
Expected/observed mortality ratio 1.20 1.16 1.21 1.14 1.07 0.95 0.90 0.91 0.73 0.80
Risk-adjusted mortality (%) 3.53% 3.42% 3.58% 3.35% 3.15% 2.79% 2.64% 2.66% 2.16% 2.36%
Observed stroke (%) 1.7% 1.9% 1.6% 1.6% 1.6% 1.7% 1.4% 1.4% 1.5% 1.3%
Mean postoperative stay (d) 8 7.9 7.8 7.8 7.8 7.8 7.8 7.8 7.7 7.8
Mean age (y) 65.9 66.2 66.2 67.0 66.9 66.9 66.9 67.0 67.3 67.9
Mechanical valve (%) 49.9% 43.9% 40.7% 37.9% 34.3% 31.9% 28.8% 27.0% 24.4% 20.5%
Bioprosthetic valve (%) 43.6% 48.3% 50.7% 56.4% 62.1% 65.8% 69.3% 70.8% 74.3% 78.4%
Mechanical and bioprosthetic valves (%) 93.5% 92.2% 91.4% 94.3% 96.4% 97.8% 98.1% 97.8% 98.8% 98.9%
Ratio of bioprosthetic to mechanical valves 0.466 0.524 0.555 0.598 0.644 0.673 0.706 0.724 0.753 0.792adverse outcome rate and could possibly be manipulated to
ameliorate it are unclear, however, and will require further
study. Increased adverse outcomes in the nonwhite patients
were also observed in this study. This observation in the
setting of heart surgery has also been made in previous re-
ports.18 Again, the study design of this review was not suf-
ficient to explain this finding.
The dramatic shift away from mechanical heart valves
toward bioprosthetic heart valves is difficult to explain
because of the relatively short time frame in which it oc-
curred. Nonetheless, many young patients refuse long-term
anticoagulation, and elderly patients are at high risk when
receiving anticoagulation. There has been evidence that
reoperation to replace a failed bioprosthetic valve can be
accomplished with good outcomes driven by factors
other than simple replacement of the valve, such as age,
degree of heart failure, and coronary disease.19,20 Newer
generation tissue valves are expected to provide longer re-
operation-free survivals. Finally, the population of patients
has aged during the study period, and it is expected that
the elderly segment of the population will continue to
grow dramatically. Multiplying and adding risk through
the patient’s lifetime to derive a predicted total lifetime
FIGURE 2. Risk-adjusted mortality for aortic valve replacement during 10
years in Society of Thoracic Surgeons database. Mortality for aortic valve
replacement decreased with time. Asterisk indicates P< .01.88 The Journal of Thoracic and Cardiovascular Surrisk for valve implantation at the time of the index
operation favors a bioprosthetic valve over mechanical
valve and may explain the finding in this study of a nation-
wide shift toward bioprosthetic valves.21 All these factors
taken together have influenced surgeon and patient valve
choices.
In conclusion, predicted risk and comorbidities of patients
undergoing AVR have increased during the last 10 years in
this country. Despite these changes, outcomes, including
rates of death and stroke, not only have improved but are
quite low for isolated AVR. There has been a dramatic shift
toward the use of bioprosthetic valves during the 10-year
study period. Female sex is associated with higher rates of
death and adverse outcomes in the setting of isolated
AVR, a finding that requires a search for cause.
Study Limitations
This study was based on the STS database and therefore
by definition was a retrospective review of patient data
submitted by participating centers. Furthermore, the cases
studied were nonconsecutive and based on voluntary par-
ticipation in the STS database. In addition, this was a study
FIGURE 3. Stroke rate after aortic valve replacement (AVR) in Society of
Thoracic Surgeons database from 1997 through 2006. Stroke rate decreased
during 10-year study period. Asterisk indicates P< .01.gery c January 2009
Brown et al Acquired Cardiovascular Disease
A
C
DTABLE 5. Changes in outcome between 1997 and 2006 by subgroup
Mortality Stroke
N Rate (%) Relative change (%) Rate (%) Relative change (%)
1997 2006 1997 2006 Value
95% Confidence
interval P value 1997 2006 Value
95% Confidence
interval P value
All 9407 15,397 3.4% 2.6% 24.3% 35.1% to11.6% <.01 1.7% 1.3% 21.1% 35.9% to2.9% .03
Male
No 4025 6,570 4.1% 3.2% 20.8% 35.3% to3.0% .02 2.0% 1.4% 28.1% 45.6% to5.1% .02
Yes 5382 8,827 2.8% 2.1% 27.9% 42.6% to9.4% <.01 1.4% 1.2% 13.7% 36.1% to 16.5% .34
Nonwhite
No 8452 13,552 3.3% 2.5% 24.5% 36.1% to10.7% <.01 1.6% 1.3% 15.3% 32.3% to 5.9% .15
Yes 955 1,845 4.4% 3.3% 26.1% 49.8% to 8.9% .13 2.5% 1.2% 52.6% 73.1% to16.5% <.01
Age 70 y
No 4946 7,368 2.2% 1.3% 43.8% 57.4% to25.7% <.01 1.2% 0.7% 43.3% 62.7% to13.9% <.01
Yes 4461 8,029 4.6% 3.7% 19.1% 32.8% to2.6% .02 2.2% 1.9% 13.9% 32.5% to 9.8% .23
Diabetes
No 7953 11,481 2.8% 2.2% 24.0% 36.9% to8.4% <.01 1.4% 1.3% 8.2% 27.6% to 16.3% .48
Yes 1454 3,916 6.3% 3.7% 41.1% 53.8% to24.8% <.01 3.0% 1.4% 55.3% 69.7% to34.0% <.01
Peripheral vascular disease
No 8636 13,998 3.0% 2.3% 24.6% 36.3% to10.9% <.01 1.6% 1.3% 19.0% 36.0% to 2.6% .08
Yes 771 1,399 7.1% 5.2% 26.9% 48.9% to 4.6% .09 3.1% 2.0% 35.7% 62.8% to 11.0% .11
Previous valve surgery
No 8747 14,581 3.3% 2.4% 27.0% 38.0% to14.0% <.01 1.7% 1.3% 21.6% 36.8% to2.8% .03
Yes 660 816 4.8% 5.6% 16.3% 25.6% to 81.6% .51 1.7% 1.5% 11.8% 60.4% to 96.7% .76
Myocardial infarction
No 8648 13,839 3.1% 2.2% 28.3% 39.4% to15.1% <.01 1.6% 1.1% 29.5% 43.6% to11.9% <.01
Yes 759 1,558 6.1% 5.3% 13.2% 39.6% to 24.9% .45 2.2% 2.9% 29.0% 23.9% to 118.5% .34
Congestive heart failure
No 5526 10,201 2.1% 1.6% 23.6% 40.0% to2.7% .03 1.4% 1.2% 17.4% 37.2% to 8.8% .17
Yes 3881 5,196 5.2% 4.4% 14.9% 29.9% to 3.4% .10 2.1% 1.6% 20.6% 41.9% to 8.4% .15
Urgent operation
No 7959 12,059 2.8% 1.9% 31.9% 43.4% to18.1% <.01 1.6% 1.2% 23.8% 39.7% to3.6% .02
Yes 1448 3,338 6.5% 4.9% 24.8% 41.8% to2.7% .03 2.0% 1.6% 17.7% 47.5% to 28.9% .39
Ejection fraction<30%
No 8960 14,682 3.2% 2.4% 14.3% 46.2% to 36.5% .52 1.7% 1.3% 9.7% 61.3% to 110.5% .81
Yes 447 715 6.0% 5.2% 25.1% 36.2% to12.0% <.01 2.0% 1.8% 21.8% 36.6% to3.5% .02
Body mass index 30 kg/m2
No 6832 9,587 3.5% 2.7% 21.9% 35.0% to6.1% <.01 1.8% 1.5% 17.4% 35.0% to 4.8% .12
Yes 2575 5,810 3.0% 2.3% 25.6% 42.8% to3.1% .03 1.2% 1.0% 19.7% 47.1% to 21.9% .30
Renal failure
No 9026 14,548 2.9% 2.2% 24.6% 36.2% to10.8% <.01 1.6% 1.3% 17.9% 33.6% to 1.6% .07
Yes 381 849 13.9% 8.5% 39.0% 55.6% to16.2% <.01 4.2% 1.9% 55.1% 76.5% to14.4% .01
Age (y)
<55 1857 2,470 1.5% 0.9% 38.7% 64.8% to 6.6% .08 0.6% 0.5% 18.0% 63.5% to 84.4% .63
55 to<60 719 1,344 2.2% 0.6% 73.3% 88.5% to37.9% <.01 1.1% 0.2% 79.9% 94.5% to26.2% .01
60 to<65 1000 1,595 3.2% 1.6% 51.0% 70.7% to18.0% <.01 1.1% 0.9% 14.5% 61.3% to 89.1% .70
65 to<70 1370 1,959 2.6% 1.9% 26.2% 52.9% to 15.7% .19 2.0% 1.0% 52.5% 74.5% to11.8% .02
70 to<75 1654 2,283 3.2% 2.9% 9.8% 37.4% to 30.0% .58 1.9% 1.5% 23.0% 51.9% to 23.2% .28
75 to<80 1547 2,707 4.6% 3.3% 29.2% 47.6% to4.2% .03 2.3% 2.1% 5.3% 37.4% to 43.3% .80
80 to<85 911 2,180 6.3% 4.9% 22.3% 42.9% to 5.8% .11 2.2% 2.0% 10.2% 45.0% to 46.8% .67
85 to<90 294 765 7.8% 4.1% 48.2% 69.0% to13.5% .01 4.1% 2.4% 42.4% 71.9% to 18.4% .13
90 55 94 3.6% 9.6% 163.3% 40.2% to 1059.2% .20 1.8% 2.1% 17.0% 89.2% to 1168.6% .90
Missing data were imputed to the no category.of AVR only. New pioneering therapies, such as aggres-
sive and effective repair techniques for aortic insufficiency,
will change the focus to short- and long-term outcomesThe Journal of Thoracic andfrom treatment of a disease rather than outcomes from
a particular procedure.22 Long-term data cannot yet be
linked to the in-hospital and 30-day outcome measuresCardiovascular Surgery c Volume 137, Number 1 89
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Dprovided by the STS database. Further investigation will
require inclusion of long-term outcomes and health-related
quality of life in any assessment of surgical therapy of
valve disease.
References
1. Reardon MJ, Reardon PR, Baldwin JC. The evolution of aortic valve surgery.
Contemp Surg. 1997;50:161-8.
2. Ferguson TB Jr, Hammill BG, Peterson ED, DeLong ER, Grover FL. A decade of
change—risk profiles and outcomes for isolated coronary artery bypass grafting
procedures, 1990-1999: a report from the STS National Database Committee
and the Duke Clinical Research Institute. Society of Thoracic Surgeons. Ann
Thorac Surg. 2002;73:480-90.
3. Edwards FH, Peterson ED, Coombs LP, DeLong ER, Jamieson WR, Shroyer AL,
et al. Prediction of operative mortality after valve replacement surgery. J Am Coll
Cardiol. 2001;37:885-92.
4. Goland S, Czer LS, De Robertis MA, Mirocha J, Kass RM, Fontana GP, et al.
Risk factors associated with reoperation and mortality in 252 patients after aortic
valve replacement for congenitally bicuspid aortic valve disease. Ann Thorac
Surg. 2007;83:931-7.
FIGURE 4. Mortality from aortic valve replacement among male and fe-
male patients. Female patients had greater mortality in 1997, in 2006, and
in overall population. Asterisk indicates P< .01.
FIGURE 5. Mortality versus age in aortic valve replacement study popu-
lation. Mortality was age dependent in 1997 and in 2006. For age groups as
shown, mortality was less in 2006 than in 1997. Asterisk indicates P< .05.90 The Journal of Thoracic and Cardiovascular Surg5. Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy cases.
Am J Cardiol. 1970;26:72-83.
6. Freeman RV Otto CM. Spectrum of calcific aortic valve disease: pathogenesis,
disease progression, and treatment strategies. Circulation. 2005;111:3316-26.
7. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-
Sarano M. Burden of valvular heart disease: a population-based study. Lancet.
2006;368:1005-11.
8. Day CJ. Population projections of the united states by age, sex, race and Hispanic
origin: 1995 to 2050. Curr Popul Rep Popul Estim Proj. 25–1130.
9. Chiappini B CN, Loforte A, Di Marco L, Di Bartolomeo R, Marinelli G. Outcome
after aortic valve replacement in octogenarians. Ann Thorac Surg. 2004;78:
85-9.
10. Walther T, Mohr FW. Aortic valve surgery: time to be open-minded and to re-
think. Eur J Cardiothorac Surg. 2007;31:4-6.
11. Vassiliades TA Jr, Block PC, Cohn LH, Adams DH, Borer JS, Feldman T, et al.
The clinical development of percutaneous heart valve technology. J Am Coll Car-
diol. 2005;45:1554-60.
12. Ambler G Omar RZ, Royston P, Kinsman R, Keogh BE, Taylor KM. Generic,
simple risk stratification model for heart valve surgery. Circulation. 2005;112:
224-31.
13. Jin R, Grunkemeier GL, Starr A. Validation and refinement of mortality risk
models for heart valve surgery. Ann Thorac Surg. 2005;80:471-9.
14. Nowicki ER, Birkmeyer NJ, Weintraub RW, Leavitt BJ, Sanders JH, Dacey LJ,
et al. Multivariable prediction of in-hospital mortality associated with aortic and
mitral valve surgery in Northern New England. Ann Thorac Surg. 2004;77:
1966-77.
15. Kuduvalli M, Grayson AD, Au J, Grotte G, Bridgewater B, Fabri BM. A multi-
centre additive and logistic risk model for in-hospital mortality following aortic
valve replacement. Eur J Cardiothorac Surg. 2007;31:607-13.
16. Hannan EL, Wu C, Bennett EV, Carlson RE, Culliford AT, Gold JP, et al. Risk
index for predicting in-hospital mortality for cardiac valve surgery. Ann Thorac
Surg. 2007;83:921-9.
17. Bridges CR, O’Brien SM, Cleveland JC, Savage EB, Gammie JS, Edwards FH,
et al. Association between indices of prosthesis internal orifice size and operative
mortality after isolated aortic valve replacement. J Thorac Cardiovasc Surg. 2007;
133:1012-21.
18. Bridges CR. Cardiac surgery in African Americans. Ann Thorac Surg. 2003;76:
S1356-62.
19. Byrne JG, Aranki SF, Couper GS, Adams DH, Allred EN, Cohn LH. Reoperative
aortic valve replacement: partial upper hemisternotomy versus conventional full
sternotomy. J Thorac Cardiovasc Surg. 1999;118:991-7.
20. Jamieson WR, Burr LH, Miyagishima RT, Janusz MT, Fradet GJ, Ling H, et al.
Re-operation for bioprosthetic aortic structural failure—risk assessment. Eur J
Cardiothorac Surg. 2003;24:873-8.
21. El Oakley R, Klein P, Bach DS. Choice of prosthetic heart valve in today’s prac-
tice. Circulation. 2008;117:253-6.
22. Lausberg HF, Aicher D, Langer F, Schafers HJ. Aortic valve repair with autolo-
gous pericardial patch. Eur J Cardiothorac Surg. 2006;30:244-9.
FIGURE 6. Stroke versus age in aortic valve replacement population be-
tween 1997 and 2006. Stroke rate was age dependent but also reduced as
shown between 1997 and 2006. Asterisk indicates P< .05.ery c January 2009
